Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range of targets may overcome resistance. CDDO-Me (bardoxolone...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleixner, Karoline V., Schneeweiss, Mathias, Eisenwort, Gregor, Berger, Daniela, Herrmann, Harald, Blatt, Katharina, Greiner, Georg, Byrgazov, Konstantin, Hoermann, Gregor, Konopleva, Marina, Waliul, Islam, Cumaraswamy, Abbarna A., Gunning, Patrick T., Maeda, Hiroshi, Moriggl, Richard, Deininger, Michael, Lion, Thomas, Andreeff, Michael, Valent, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685220/
https://www.ncbi.nlm.nih.gov/pubmed/28596283
http://dx.doi.org/10.3324/haematol.2016.163436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685220/
https://www.ncbi.nlm.nih.gov/pubmed/28596283
http://dx.doi.org/10.3324/haematol.2016.163436

Ejemplares similares